Israel’s BiolineRx has reported positive results from Phase II trials of its BL-8040 treatment in relapsed or refractory acute myeloid leukemia and researchers at the Hebrew University of Jerusalem have uncovered a key gene responsible for ovary development.
By: Michael Ordman
ISRAEL’S MEDICAL ACHIEVEMENTS
Success in Leukemia treatment trials
Israel’s BiolineRx has reported positive results from Phase II trials of its BL-8040 treatment in relapsed or refractory acute myeloid leukemia (r/r AML). It had a triple positive effect on the leukemic cells only two days after a single cycle of therapy.
Genetic mutation explains how ovaries develop
Researchers at the Hebrew University of Jerusalem have uncovered a key gene responsible for ovary development. Four members of the same family had mutated Nup107 genes causing infertility. The discovery has widespread implications for research in cell biology.
US can now access Israeli stem cell research
For over 30 years Israel’s Biological Industries has been providing cell culture media development, molecular and diagnostics tools, and stem cell research products in more than 50 countries. It now has set-up its first USA division in Cromwell Connecticut.
US approval for unique Israeli dialysis device
The US FDA has approved the Chameleon from Israel’s AV Medical Technologies. Chameleon is the world’s first and only angioplasty balloon catheter that allows for simultaneous balloon inflation and intravascular injection of fluids while maintaining guidewire access. Over two million angioplasty balloon catheters are used annually worldwide to maintain dialysis access.
Prize for discovering link from brain to immune system
On the anniversary of Chaim Weizmann’s death, KKL-JNF awarded the Blumberg Outstanding Medical Research Scientist Prize to Weizmann Professor Michal Schwartz for her groundbreaking research into the connection between the brain and the immune system.
Click here for all of this week’s Good News from Israel.